Gilead Sciences, Inc.
NEWS
Veru posted positive interim Phase III data from its late-stage study assessing oral antiviral sabizabulin in hospitalized COVID-19 patients. Here’s more about it.
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.
Kite Pharma, a subsidiary of Gilead, announced that its Yescarta® has been approved by the U.S. Food and Drug Administration (FDA).
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Gilead Sciences posted some good news: a late-stage study of its antibody-drug conjugate Trodelvy shows promise in slowing the progression of the most common forms of breast cancer.
The FDA rejected Gilead’s New Drug Application, citing Chemistry Manufacturing and Controls (CMC) problems associated with the compatibility of the drug with the proposed container vial.
The end of February picks up significantly from early this year for the U.S. Food and Drug Administration and its PDUFA dates.
BioSpace compared the 43 healthcare and life science companies on Newsweek’s list of America’s Most Responsible Companies for 2022 with that of our own 2022 Best Places to Work.
JOBS
IN THE PRESS